Reply: Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease

Abstract

Get full access to this article

View all access options for this article.

References

Peh

Narayanaswamy

Wang

. Comment: safety and efficacy of apixaban versus warfarin in patients with advanced chronic kidney disease. Ann Pharmacother. 2019;53:101-102.

Rivosecchi

Groetzinger

Miller

. Comment: safety and efficacy of apixaban versus warfarin in patients with advanced chronic kidney disease. Ann Pharmacother. 2019;53:103.

Wang

Tirucherai

Marbury

et al . Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016;56:628-636. doi:10.1002/jcph.628

Mavrakanas

Samer

Nessim

Frisch

Lipman

ML.

Apixaban pharmacokinetics at steady state in hemodialysis patients. J Am Soc Nephrol. 2017;28:2241-2248. doi:10.1681/ASN.2016090980

Shah

Tsadok

Jackevicius

et al . Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation. 2014;129:1196-1203. doi:10.1161/CIRCULATIONAHA.113.004777

Siontis

Zhang

Eckard

et al . Outcomes associated with apixaban use in end-stage kidney disease patients with atrial fibrillation in the united states. Circulation. 2018;138:1519-1529.